Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial
Publication date: December 2020Source: The Lancet Diabetes & Endocrinology, Volume 8, Issue 12Author(s): Darren K McGuire, Bernard Zinman, Silvio E Inzucchi, Christoph Wanner, David Fitchett, Stefan D Anker, Stuart Pocock, Stefan Kaspers, Jyothis T George, Maximilian von Eynatten, Odd Erik Johansen, Waheed Jamal, Michaela Mattheus, Ulrich Elsasser, Stefan Hantel, Søren S Lund
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Jardiance